The Risk Intelligent life sciences companyRisk Intelligence Series, no.4 |
The life sciences industry (pharmaceuticals, biotechnology and medical devices) faces significant risks inherent in the business. Executives and directors must address the continual demands of a multitude of constituents - regulators, investors, partners, insurers, physicians, patients, lawyers, media and others. Meeting these needs adds complexity and heightens risk, and as these risks converge and overlap, managing risk becomes simultaneously more difficult and more essential.
The fourth title in Deloitte's Risk Intelligence Series provides practical guidance and real-world examples of how to more effectively address the industry’s complex risk matrix, and cites a number of fundamental steps organisations need to undertake to create a Risk Intelligent Enterprise.
To view the entire paper, download the document below.
Related Content:
Resources: The Risk Intelligent Enterprise
Issue no.8:
The Risk Intelligent approach to offshoring and outsourcing
Issue no.7:
The Risk Intelligent energy company: weathering the storm of climate change
Issue no.6:
The Risk Intelligent CIO: Becoming a front-line IT leader in a risky world
Issue no.5:
The Risk Intelligent Chief Audit Executive
Issue no.3:
The Risk Intelligent enterprise: ERM for the energy industry
Issue no.2:
Risk Intelligence in the age of global uncertainty
Issue no.1:
ERM done right - the Risk Intelligent enterprise
Attachments
The risk intelligent life sciences company (PDF, 151 KB)
A Deloitte US report
